Evaluation of the stability of furosemide in tablet form during six-month storage in spaceflight and peculiarities of its pharmacokinetics and pharmacodynamics under conditions of anti-orthostatic hypokinesia.
anti-orthostatic hypokinesia
furosemide
hemodynamics
pharmacodynamics
pharmacokinetics
spaceflight
stability
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
07
06
2021
accepted:
28
11
2021
pubmed:
27
2
2022
medline:
16
9
2022
entrez:
26
2
2022
Statut:
epublish
Résumé
The present study investigated the stability of furosemide under space-flight conditions on board the International Space Station, as well as its pharmacokinetics and pharmacodynamics under conditions simulating exposure to some space-flight factors. Quantitative analysis of furosemide tablets by HPLC was performed before spaceflight (background), then after six months storage under normal ground conditions (control) and under spaceflight conditions (SF). The pharmacokinetics and pharmacodynamics of furosemide were studied in six healthy volunteers after a single oral dose of 40 mg under normal conditions (background) and under anti-orthostatic hypokinesia (ANOH). Quantitative content of furosemide in tablets before SF was 40.19 ± 0.28 mg (100.47 ± 0.71%), after 6 months storage: under normal conditions (control) - 39.9 ± 0.39 mg (99.73 ± 0.98%), under SF - 39.24 ± 0.72 mg (98.11 ± 1.80%), which was within the prescribed limits. Studying basic hemodynamic parameters showed that in ANOH conditions 6 h after furosemide administration there was a statistically significant increase of the stroke volume (SV) (+36.5 Δ%), a tendency for increasing of the stroke index (SI) (+36.5 Δ%) and decreasing of the total peripheral resistance (TPR) (-21.9 Δ%) compared to baseline study. It has been established that various factors of space flight (overloading, excessive vibration, microgravity, etc.) do not negatively influence the stability of furosemide in tablet form during storage for 6 months on board the International Space Station.
Identifiants
pubmed: 35218179
pii: dmdi-2021-0149
doi: 10.1515/dmpt-2021-0149
doi:
Substances chimiques
Tablets
0
Furosemide
7LXU5N7ZO5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-259Informations de copyright
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Références
Blue, RS, Bayuse, TM, Daniels, VR, Wotring, VE, Suresh, R, Mulcahy, RA, et al.. Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. NPJ Microgravity 2019;5:14. https://doi.org/10.1038/s41526-019-0075-2.
Blue, RS, Chancellor, JC, Antonsen, EL, Bayuse, TM, Daniels, VR, Wotring, VE. Limitations in predicting radiation-induced pharmaceutical instability during long-duration spaceflight. NPJ Microgravity 2019;5:15. https://doi.org/10.1038/s41526-019-0076-1.
Braddock, M. Ergonomic challenges for astronauts during space travel and the need for space medicine. J Ergon 2017;7:221. https://doi.org/10.4172/2165-7556.1000221.
Eyal, S. How do the pharmacokinetics of drugs change in astronauts in space? Expert Opin Drug Metab Toxicol 2020;16:353–6. https://doi.org/10.1080/17425255.2020.1746763.
Kast, J, Yu, Y, Seubert, CN, Wotring, VE, Derendorf, H. Drugs in space: pharmacokinetics and pharmacodynamics in astronauts. Eur J Pharm Sci 2017;109S:S2–S8. https://doi.org/10.1016/j.ejps.2017.05.025.
Iosim, S, MacKay, M, Westover, C, Mason, CE. Translating current biomedical therapies for long duration, deep space missions. Precis Clin Med 2019;2:259–69. https://doi.org/10.1093/pcmedi/pbz022.
Eyal, S, Derendorf, H. Medications in space: in search of a pharmacologist’s guide to the galaxy. Pharm Res 2019;36:148. https://doi.org/10.1007/s11095-019-2679-3.
Benson, S, Cable, G, Workman, L. Challenges in anaesthesia during space exploration missions. J Aust Soc Aerosp Med 2019;11:1–10. https://doi.org/10.21307/asam-2019-002.
Chancellor, JC, Blue, RS, Cengel, KA, Auñón-Chancellor, SM, Rubins, KH, Katzgraber, HG, et al.. Limitations in predicting the space radiation health risk for exploration astronauts. NPJ Microgravity 2018;4:8. https://doi.org/10.1038/s41526-018-0043-2.
Wotring, V. Spaceflight pharmacology. In: Barratt, M, Baker, E, Pool, S, editors. Principles of clinical medicine for space flight. New York, NY: Springer; 2019. pp. 815–40. https://doi.org/10.1007/978-1-4939-9889-0_27.
Du, B, Daniels, VR, Vaksman, Z, Boyd, JL, Crady, C, Putcha, L. Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J 2011;13:299–308. https://doi.org/10.1208/s12248-011-9270-0.
Wotring, VE. Absorption. In: Space Pharmacology. SpringerBriefs in Space Development. Boston, MA: Springer; 2012. https://doi.org/10.1007/978-1-4614-3396-5_2.
Kohn, FPM, Hauslage, J. The gravity dependence of pharmacodynamics: the integration of lidocaine into membranes in microgravity. NPJ Microgravity 2019;5:5. https://doi.org/10.1038/s41526-019-0064-5.
Grigoriev, AI. General mechanisms of the effects of weightlessness on the human. In: Bonting, SL, editor. Advan. in space biology and medicine. London: JAI Press Inc.; 1992, vol 2. pp. 1–42. https://doi.org/10.1016/s1569-2574(08)60016-7.
Cintron, NM, Lane, HW, Leach, CS. Metabolic consequences of fluid shifts induced by microgravity. Physiologist 1990;33(1 Suppl):S16-9. https://pubmed.ncbi.nlm.nih.gov/2196599/.
Kovachevich, IV, Kondratenko, SN, Starodubshev, AK, Repenkova, LG. Pharmacokinetics of tablet and capsule formulations of acetaminophen in conditions of prolonged space flight. Pharm Chem J 2009;43:130–3. https://doi.org/10.1007/s11094-009-0255-6.
Tietze, KJ, Putcha, L. Factors affecting drug bioavailability in space. J Clin Pharmacol 1994;6:671–6. https://doi.org/10.1002/j.1552-4604.1994.tb02022.x.
Goncharov, IB, Kovachevich, IV. The system of rendering medical aid to astronauts. In: Orbital station «Mir»: Space biology and medicine. V.1. Medical support of long-term missions. Moscow: State Scientific Center of the Russian Federation - Institute of Medical and Biological Problems of the Russian Academy of Sciences; 2001.
Ramenskaya, GV, Kondratenko, SN, Krasnykh, LM. Methods of quantitative determination of drugs in the blood plasma of patients by high performance liquid chromatography. In: Clinical pharmacokinetics: theoretical, applied and analytical aspects. Moscow: GEOTAR-Media; 2009.
State Pharmacopoeia of the Russian Federation. The XIV edition. Moscow: Ministry of Health of the Russian Federation; 2018.
Ram, VR, Dave, PN, Joshi, HS. Development and validation of a stability-indicating HPLC assay method for simultaneous determination of spironolactone and furosemide in tablet formulation. J Chromatogr Sci 2012;50:721–6. https://doi.org/10.1093/chromsci/bms062.
Bondareva, IB, Budanov, SV, Bunyatyan, ND, Zherdev, VP, Kolyvanov, GB, Kondratenko, SN, et al.. Bioequivalence assessment of drugs. Moscow: Scientific Center Expertise of Medical Applications; 2008.
Miroshnichenko, II, Tyulyaev, II, Zuev, AP. Bioavailability of drugs. Moscow: Gramotey; 2003.
Agafonov, AA, Piotrovskii, VK. M-IND software for evaluation of pharmacokinetic system parameters by the model-independent method of statistical moments. Khim Farm Zh 1991;25:16–9.
Sergienko, VI, Jelliffe, R, Bondareva, IB. Applied pharmacokinetics: basic provisions and clinical application. Moscow: RAMS Publishing House; 2003.
Luts, RJ, Dedrick, RL, Matthews, HB, Eling, TE, Anderson, MW. A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat. Drug Metab Disp 1977;5:386–96. https://pubmed.ncbi.nlm.nih.gov/19218/.
United States Pharmacopeia and National Formulary (USP40-NF35). United States Pharmacopeial Convention, Rockville, MD, 2016.
Hanna, GM, Lau-Cam, CA. Stability-indicating proton nuclear magnetic resonance spectroscopic assay method for furosemide in tablets and injections. J AOAC Int 1993;76:526–30. https://doi.org/10.1093/jaoac/76.3.526.
Carda-Broch, S, Esteve-Romero, J, García-Alvarez-Coque, MC. Furosemide assay in pharmaceuticals by micellar liquid chromatography: study of the stability of the drug. J Pharm Biomed Anal 2000;23:803–17. https://doi.org/10.1016/s0731-7085(00)00378-2.
Chuong, MC, Prasad, D, Leduc, B, Du, B, Putcha, L. Stability of vitamin B complex in multivitamin and multimineral supplement tablets after space flight. J Pharm Biomed Anal 2011;5:1197–200. https://doi.org/10.1016/j.jpba.2011.03.030.
Gazenko, OG, Grigoriev, AI, Natochin, YuV. Water-salt homeostasis and space flight. Moscow: Nauka; 1986.
Polyakov, AV, Svistunov, AA, Kondratenko, SN, Kovachevich, IV, Repenkova, LG, Savelyeva, MI, et al.. Peculiarities of pharmacokinetics and bioavailability of some cardiovascular drugs under conditions of antiorthostatic hypokinesia. Bull Exp Biol Med 2020;168:465–9. https://doi.org/10.1007/s10517-020-04732-w.
Hammarlund-Udenaes, M, Benet, LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease–an update. J Pharmacokinet Biopharm 1989;17:1–46. https://doi.org/10.1007/bf01059086.
Kelly, MR, Cutler, RE, Forrey, AW, Kimpel, BM. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther 1974;15:178–86. https://doi.org/10.1002/cpt1974152178.
Fritsch, JM, Rea, RF, Eckberg, DL. Carotid baroreflex resetting during drug-induced arterial pressure changes in humans. Am J Physiol 1989;256 (2 Pt 2):R549–553. https://doi.org/10.1152/ajpregu.1989.256.2.R549.
Fritsch-Yelle, JM, Charles, JB, Jones, MM, Beightol, LA, Eckberg, DL. Spaceflight alters autonomic regulation of arterial pressure in humans. J Appl Physiol 1994;77:1776–83. https://doi.org/10.1152/jappl.1994.77.4.1776.
Noskov, VB. The effect of body position and diuretic administration on the water-salt status and kidney activity. Hum Physiol 1982;8:638.